EL7.AI
StocksUpdated•Originally published 19 July 2026•Updated 19 July 2026•
2 min read

Microsoft and Regeneron Hit with Class Action Lawsuits Over Alleged Investor Deception

Yellow folder stamped 'Class Action' with Microsoft AI server, Regeneron vial, and justice scales on orange background.

Key Facts

1A class action lawsuit was filed against Microsoft alleging misleading statements regarding Copilot AI products and competitive performance.
2Regeneron Pharmaceuticals faces a lawsuit alleging false statements concerning its Phase III Fianlimab-Libtayo study.

Amid intensifying legal scrutiny on Big Tech and the biotech sector, class action lawsuits have been filed against Microsoft and Regeneron Pharmaceuticals for alleged securities law violations. Microsoft is accused of making misleading statements regarding its Copilot AI products and their competitive standing. Simultaneously, Regeneron faces allegations of providing false information concerning its Phase III study of the drug Fianlimab-Libtayo, raising concerns over the transparency of corporate disclosures.

These legal actions arrive at a critical juncture for the tech industry, as companies face pressure to demonstrate financial returns from massive AI investments. In comparison to peers, Apple (AAPL) closed at $333.74 and Meta (META) at $646.01 per market data (close July 17, 2026). Such class actions, initiated by firms like Bronstein, Gewirtz & Grossman, often lead to protracted litigation which can weigh on investor sentiment in the short term, despite being common for mega-cap entities.

Regarding current price levels, MSFT stood at $393.82 at close July 17, 2026, while REGN closed at $678.94 on July 16, 2026. Traders should monitor further legal developments that could impact forward guidance, especially as the market prepares for upcoming commentary from Fed officials, including speeches by Governors Bowman and Waller, which may influence broader market liquidity and sector-specific sentiment.